Clinical Trial Update: FOLFIRINOX + NIS793 in Pancreatic Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of FOLFIRINOX and NIS793 in pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• FOLFIRINOX
• NIS793 (NIS-793)

Snippet

Sponsor: Colin D. Weekes, M.D., PhD | Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer | Phase 1 | Status: TERMINATED